iTolerance, Inc. Closes $17.1 Million Convertible Note Financing to Advance Development of Innovative Regenerative Medicines for Transplantation Without the Need for Life-Long Immunosuppression - Seite 2
iTolerance's lead program iTOL-101 is being developed as a potential cure for Type 1 Diabetes. Using the iTOL-100 platform technology, allogenic pancreatic islets are co-implanted and in pre-clinical studies have shown immune acceptance and long-term function of the graft with control of blood glucose levels and restoration of insulin secretion without the need for immunosuppression. The Company is moving forward with pre-clinical studies to support a Phase 1/2 study in Type 1 Diabetes.
The Company's second lead program, iTOL-102, utilizes the iTOL-100 platform technology to induce local immune tolerance and leverages significant advancements in stem cell-derived pancreatic islets which allows an inexhaustible supply of insulin-producing cells as a potential cure for Type 1 Diabetes without the need for life-long immunosuppression.
About iTolerance, Inc.
Lesen Sie auch
iTolerance is an early stage privately held regenerative medicine company developing technology to enable tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging its proprietary biotechnology-derived Strepavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL microgel) platform technology, iTOL-100, iTolerance is advancing a pipeline of programs using both allogenic pancreatic islets and stem cells that have the potential to cure diseases. The Company's lead program, iTOL-101 is being developed for Type 1 Diabetes and in a pre-clinical non-human primate study, pancreatic islet cells co-implanted with iTOL-101 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. The Company's second lead candidate, iTOL-102, is leveraging significant advancements in stem cells to derive pancreatic islets which allows an inexhaustible supply of insulin-producing cells. Utilizing iTOL-100 to induce local immune tolerance, iTOL-102 has the potential to be a cure for Type 1 Diabetes without the need for life-long immunosuppression. Additionally, the Company is developing iTOL-201 for liver failure and iTOL-301 as a potential regenerative protein and cell therapy that leverages stem cell sources to produce proteins or hormones in the body in conditions of high unmet need without the need for life-long immunosuppression. For more information, please visit itolerance.com.